NCT05411146View on ClinicalTrials.gov

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

July 7, 2022

Study Completion Date

July 7, 2022

Conditions
Healthy Participants
Interventions
DRUG

[14C]-etrumadenant

Administered as specified in the treatment arm.

Trial Locations (1)

9728

PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Arcus Biosciences, Inc.

INDUSTRY

NCT05411146 - A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer | Biotech Hunter | Biotech Hunter